Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy

Cancer immunotherapy has altered the management of human malignancies, improving outcomes in an expanding list of diseases. Breast cancer - presumably due to its perceived low immunogenicity - is a late addition to this list. Furthermore, most of the focus has been on the triple negative subtype bec...

Descripción completa

Detalles Bibliográficos
Autores principales: Chrétien, Sebastian, Zerdes, Ioannis, Bergh, Jonas, Matikas, Alexios, Foukakis, Theodoros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562626/
https://www.ncbi.nlm.nih.gov/pubmed/31060337
http://dx.doi.org/10.3390/cancers11050628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562626/
https://www.ncbi.nlm.nih.gov/pubmed/31060337
http://dx.doi.org/10.3390/cancers11050628

Ejemplares similares